Monday, 17 March 2014

USP Pharmacopeial : 40(1) In-Process Revision



Future planned revisions to the USP include:
  • 51 Antimicrobial Effectiveness Testing (USP38-NF33)
  • 209 Low Molecular Weight Heparin Molecular Weight Determinations [NEW] (USP38-NF33)
  • 251 Lead (USP38-NF33)
  • 660 Containers - Glass (USP38-NF33)
  • 852 Atomic Absorption Spectroscopy [NEW] (USP38-NF33)
  • 85> Fluorescence Spectroscopy [NEW] (USP38-NF33)
  • 854 Mid-Infrared Spectroscopy [NEW] (USP38-NF33)
  • 857 Ultraviolet-Visible Spectroscopy [NEW] (USP38-NF33)
  • 1852 Atomic Absorption Spectroscopy - Theory and Practice [NEW] (USP38-NF33)
  • 1853 Fluorescence Spectroscopy - Theory and Practice [NEW] (USP38-NF33)
  • 1854 Mid-Infrared Spectroscopy - Theory and Practice [NEW] (USP38-NF33)


According to the USP:

“This section contains proposals for adoption as official USP or NF standards (either proposed new standards or proposed revisions of current USP or NF standards). These may be any of the following: (1) proposed revisions placed directly under In-Process Revision, or (2) modifications of revisions previously proposed under In-Process Revision. Readers should review material in this section and provide comments to the Scientific Liaison using the contact information appearing at the end of each proposal. Information on how to comment can be found under the "Participation" section of www.usp.org. It is important to send comments promptly, using the comment deadline listed after each title."

The U.S. Pharmacopeial Convention (USP) is a scientific nonprofit organization that sets standards for the identity, strength, quality, and purity of medicines, food ingredients, and dietary supplements manufactured, distributed and consumed worldwide. USP’s drug standards are enforceable in the United States by the Food and Drug Administration, and these standards are used in more than 140 countries.
Posted by Tim Sandle

Special offers